colorectal cancer, pancreatic cancer
Conditions
Interventions
Hochuekkitou, gosyajinnkigan, keisibukuryogan
control
Sponsors
Osaka Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: "(1) Histological proven adenocarcinoma (2) possible oral intake (3) unresectable corolectal and pancreatic cancer (4) KRAS mutation untested or negative or positive (5) PS 0-1 (6) Adequate organ function (7) Written informed consent from patients (8) Capcitabine + Oxalipltain + Bevacizumab regimen in patients with colorectal cancer (9) Gemcitabine + Nab-paclitaxel in patients with pancreatic cancer (10) Best surpotive care in study2"
Exclusion criteria
Exclusion criteria: "(1) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. (2) Past history of severe hypersensitivity to drugs (3) Body temperature of over 38 degrees Celsius or active infection (4) serious bone marrow suppression, a renal damage or a liver damage (5) Severe complications (6) Pregnant women, women with the possibility of the pregnancy, or men who want their partners to become pregnant (7) Psychological disorder (8) Patients judged inappropriate for the study by the physicians "
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MTD, RD,IL-6 | — |
Secondary
| Measure | Time frame |
|---|---|
| QOL Nutritional assessment | — |
Countries
Japan
Contacts
Public ContactToshifumi Yamaguchi
Osaka Medical College Hospital Chemotherapy Center
Outcome results
None listed